GRFP N Stock Overview
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Grifols, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €156.59 |
| 52 Week High | €165.16 |
| 52 Week Low | €120.10 |
| Beta | 0.67 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -57.18% |
| 5 Year Change | -54.77% |
| Change since IPO | -35.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| GRFP N | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how GRFP N performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how GRFP N performed against the MX Market.
Price Volatility
| GRFP N volatility | |
|---|---|
| GRFP N Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: GRFP N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GRFP N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1909 | 23,744 | Nacho Abia Buenache | www.grifols.com |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
Grifols, S.A. Fundamentals Summary
| GRFP N fundamental statistics | |
|---|---|
| Market cap | Mex$102.16b |
| Earnings (TTM) | Mex$1.08b |
| Revenue (TTM) | Mex$119.62b |
107.8x
P/E Ratio1.0x
P/S RatioIs GRFP N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRFP N income statement (TTM) | |
|---|---|
| Revenue | €6.59b |
| Cost of Revenue | €4.10b |
| Gross Profit | €2.49b |
| Other Expenses | €2.44b |
| Earnings | €59.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | 0.087 |
| Gross Margin | 37.84% |
| Net Profit Margin | 0.90% |
| Debt/Equity Ratio | 119.6% |
How did GRFP N perform over the long term?
See historical performance and comparison